guanfacine has been researched along with Metabolic Syndrome in 1 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bucher, BM | 1 |
| Wright, BA | 1 |
| Weiner, RL | 1 |
1 other study available for guanfacine and Metabolic Syndrome
| Article | Year |
|---|---|
Elevation of sweat chloride levels in a patient with CFTR-related metabolic syndrome receiving dexmethylphenidate and guanfacine.
Topics: Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Dexmethylphenidate Hydrochloride; Gu | 2022 |